BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jenh AM, Pham PA. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2010;8:1079-1092. [PMID: 20954872 DOI: 10.1586/eri.10.91] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections: Facing antiviral drug resistance. Journal of Gastroenterology and Hepatology 2012;27:1432-40. [DOI: 10.1111/j.1440-1746.2012.07198.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
2 De Clercq E. Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012) ?: TENOFOVIR: QUO VADIS ANNO 2012. Med Res Rev 2012;32:765-85. [DOI: 10.1002/med.21267] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hu M, Wang Q, Ma X, Yang C, Sun H, Liu J, Zhang Y, Xie Y. A Rapid and Sensitive LC Method for Determination of Diastereomeric Purity of Tenofovir Alafenamide. Chromatographia 2014;77:1399-403. [DOI: 10.1007/s10337-014-2745-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Chang Y, Kim SG, Jeong SW, Jang JY, Yoo JJ, Lee SH, Kim YS, Kim HS, Lee HW, Park S. Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. J Clin Med 2021;10:5628. [PMID: 34884330 DOI: 10.3390/jcm10235628] [Reference Citation Analysis]
5 Fernández-Rodríguez CM, Gutiérrez-García ML. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther 2014; 5(3): 175-182 [PMID: 25133046 DOI: 10.4292/wjgpt.v5.i3.175] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
6 Lin X, Liang C, Zou L, Yin Y, Wang J, Chen D, Lan W. Advance of structural modification of nucleosides scaffold. Eur J Med Chem 2021;214:113233. [PMID: 33550179 DOI: 10.1016/j.ejmech.2021.113233] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Choi JH, Kang MS, Lee CG, Wang NL, Mun S. Design of simulated moving bed for separation of fumaric acid with a little fronting phenomenon. J Chromatogr A 2017;1491:75-86. [PMID: 28249717 DOI: 10.1016/j.chroma.2017.02.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
8 Yu HM, Kwon SY, Kim J, Chung HA, Kwon SW, Jeong TG, An SH, Jeong GW, Yun SU, Min JK, Kim JH, Choe WH. Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. Saudi J Gastroenterol 2015;21:146-51. [PMID: 26021773 DOI: 10.4103/1319-3767.157558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012; 18(47): 6996-7002 [PMID: 23322999 DOI: 10.3748/wjg.v18.i47.6996] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
10 Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014;39:629-37. [PMID: 24467455 DOI: 10.1111/apt.12629] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
11 Roux L, Priet S, Payrot N, Weck C, Fournier M, Zoulim F, Balzarini J, Canard B, Alvarez K. Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study. Eur J Med Chem 2013;63:869-81. [PMID: 23603046 DOI: 10.1016/j.ejmech.2013.02.039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
12 Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, Deterding K, Dumortier J, Bailly F, Esteban R. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res. 2011;92:90-95. [PMID: 21767570 DOI: 10.1016/j.antiviral.2011.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate. J Viral Hepat. 2013;20:650-657. [PMID: 23910650 DOI: 10.1111/jvh.12088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Aljofan M, Netter HJ, Aljarbou AN, Hadda TB, Orhan IE, Sener B, Mungall BA. Anti-hepatitis B activity of isoquinoline alkaloids of plant origin. Arch Virol 2014;159:1119-28. [PMID: 24311152 DOI: 10.1007/s00705-013-1937-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
15 Barral K, Weck C, Payrot N, Roux L, Durafour C, Zoulim F, Neyts J, Balzarini J, Canard B, Priet S, Alvarez K. Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication. Eur J Med Chem 2011;46:4281-8. [PMID: 21803462 DOI: 10.1016/j.ejmech.2011.06.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]